Efficacy of brinzolamide and levobetaxolol in pediatric glaucomas: A randomized clinical trial

Jess T. Whitson, John D. Roarty, Lingam Vijaya, Alan L. Robin, Robert D. Gross, Theresa A. Landry, Jaime E. Dickerson, Sally A. Scheib, Haydn Scott, Steven Y. Hua, Adrienne M. Woodside, Michael V W Bergamini

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose: To describe the safety and clinical response on elevated intraocular pressure (IOP) of brinzolamide and levobetaxolol in pediatric patients under 6 years of age. Methods: A double-masked, randomized design. Pediatric patients were randomized to brinzolamide suspension, 1%, or levobetaxolol suspension, 0.5%, both dosed twice daily. IOPs at 9 AM were taken at screening, baseline, and weeks 2, 6, and 12. A descriptive study with mean change from baseline IOP, the primary efficacy parameter. Results: Seventy-eight evaluable patients (32 brinzolamide and 46 levobetaxolol). Patients on no prestudy IOP-lowering therapy randomized to brinzolamide had mean IOP change from baseline ranging from -4.1 mm Hg (week 2) to -5.0 mm Hg (week 6). When all brinzolamide patients are considered, there was little mean change from baseline IOP due to the large number of patients enrolled without a washout of prior IOP-lowering therapy. Levobetaxolol patients had mean change from baseline, ranging from -1.8 mm Hg (week 6) to -2.9 mm Hg (week 2). Levobetaxolol patients on no prestudy therapy had mean IOP change from baseline ranging from -2.9 mm Hg (week 12) to -4.0 mm Hg (week 2). Brinzolamide was more efficacious for glaucoma associated with systemic or ocular abnormalities and less efficacious for primary congenital glaucoma. Levobetaxolol was most efficacious for primary congenital glaucoma. Adverse events were predominantly nonserious and did not interrupt patient continuation in the study. Conclusions: Both brinzolamide and levobetaxolol were well tolerated. Both drugs provided clinically relevant IOP reductions for patients not on a previous medication, although efficacy is, in part, contingent upon diagnosis.{A figure is presented}.

Original languageEnglish (US)
JournalJournal of AAPOS
Volume12
Issue number3
DOIs
StatePublished - Jun 2008

Fingerprint

Glaucoma
Intraocular Pressure
Randomized Controlled Trials
Pediatrics
Suspensions
Eye Abnormalities
brinzolamide
Double-Blind Method
Therapeutics
Safety
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Whitson, J. T., Roarty, J. D., Vijaya, L., Robin, A. L., Gross, R. D., Landry, T. A., ... Bergamini, M. V. W. (2008). Efficacy of brinzolamide and levobetaxolol in pediatric glaucomas: A randomized clinical trial. Journal of AAPOS, 12(3). https://doi.org/10.1016/j.jaapos.2007.11.004

Efficacy of brinzolamide and levobetaxolol in pediatric glaucomas : A randomized clinical trial. / Whitson, Jess T.; Roarty, John D.; Vijaya, Lingam; Robin, Alan L.; Gross, Robert D.; Landry, Theresa A.; Dickerson, Jaime E.; Scheib, Sally A.; Scott, Haydn; Hua, Steven Y.; Woodside, Adrienne M.; Bergamini, Michael V W.

In: Journal of AAPOS, Vol. 12, No. 3, 06.2008.

Research output: Contribution to journalArticle

Whitson, JT, Roarty, JD, Vijaya, L, Robin, AL, Gross, RD, Landry, TA, Dickerson, JE, Scheib, SA, Scott, H, Hua, SY, Woodside, AM & Bergamini, MVW 2008, 'Efficacy of brinzolamide and levobetaxolol in pediatric glaucomas: A randomized clinical trial', Journal of AAPOS, vol. 12, no. 3. https://doi.org/10.1016/j.jaapos.2007.11.004
Whitson, Jess T. ; Roarty, John D. ; Vijaya, Lingam ; Robin, Alan L. ; Gross, Robert D. ; Landry, Theresa A. ; Dickerson, Jaime E. ; Scheib, Sally A. ; Scott, Haydn ; Hua, Steven Y. ; Woodside, Adrienne M. ; Bergamini, Michael V W. / Efficacy of brinzolamide and levobetaxolol in pediatric glaucomas : A randomized clinical trial. In: Journal of AAPOS. 2008 ; Vol. 12, No. 3.
@article{b7e85f03eb6241019db8ea19f66c8b95,
title = "Efficacy of brinzolamide and levobetaxolol in pediatric glaucomas: A randomized clinical trial",
abstract = "Purpose: To describe the safety and clinical response on elevated intraocular pressure (IOP) of brinzolamide and levobetaxolol in pediatric patients under 6 years of age. Methods: A double-masked, randomized design. Pediatric patients were randomized to brinzolamide suspension, 1{\%}, or levobetaxolol suspension, 0.5{\%}, both dosed twice daily. IOPs at 9 AM were taken at screening, baseline, and weeks 2, 6, and 12. A descriptive study with mean change from baseline IOP, the primary efficacy parameter. Results: Seventy-eight evaluable patients (32 brinzolamide and 46 levobetaxolol). Patients on no prestudy IOP-lowering therapy randomized to brinzolamide had mean IOP change from baseline ranging from -4.1 mm Hg (week 2) to -5.0 mm Hg (week 6). When all brinzolamide patients are considered, there was little mean change from baseline IOP due to the large number of patients enrolled without a washout of prior IOP-lowering therapy. Levobetaxolol patients had mean change from baseline, ranging from -1.8 mm Hg (week 6) to -2.9 mm Hg (week 2). Levobetaxolol patients on no prestudy therapy had mean IOP change from baseline ranging from -2.9 mm Hg (week 12) to -4.0 mm Hg (week 2). Brinzolamide was more efficacious for glaucoma associated with systemic or ocular abnormalities and less efficacious for primary congenital glaucoma. Levobetaxolol was most efficacious for primary congenital glaucoma. Adverse events were predominantly nonserious and did not interrupt patient continuation in the study. Conclusions: Both brinzolamide and levobetaxolol were well tolerated. Both drugs provided clinically relevant IOP reductions for patients not on a previous medication, although efficacy is, in part, contingent upon diagnosis.{A figure is presented}.",
author = "Whitson, {Jess T.} and Roarty, {John D.} and Lingam Vijaya and Robin, {Alan L.} and Gross, {Robert D.} and Landry, {Theresa A.} and Dickerson, {Jaime E.} and Scheib, {Sally A.} and Haydn Scott and Hua, {Steven Y.} and Woodside, {Adrienne M.} and Bergamini, {Michael V W}",
year = "2008",
month = "6",
doi = "10.1016/j.jaapos.2007.11.004",
language = "English (US)",
volume = "12",
journal = "Journal of AAPOS",
issn = "1091-8531",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Efficacy of brinzolamide and levobetaxolol in pediatric glaucomas

T2 - A randomized clinical trial

AU - Whitson, Jess T.

AU - Roarty, John D.

AU - Vijaya, Lingam

AU - Robin, Alan L.

AU - Gross, Robert D.

AU - Landry, Theresa A.

AU - Dickerson, Jaime E.

AU - Scheib, Sally A.

AU - Scott, Haydn

AU - Hua, Steven Y.

AU - Woodside, Adrienne M.

AU - Bergamini, Michael V W

PY - 2008/6

Y1 - 2008/6

N2 - Purpose: To describe the safety and clinical response on elevated intraocular pressure (IOP) of brinzolamide and levobetaxolol in pediatric patients under 6 years of age. Methods: A double-masked, randomized design. Pediatric patients were randomized to brinzolamide suspension, 1%, or levobetaxolol suspension, 0.5%, both dosed twice daily. IOPs at 9 AM were taken at screening, baseline, and weeks 2, 6, and 12. A descriptive study with mean change from baseline IOP, the primary efficacy parameter. Results: Seventy-eight evaluable patients (32 brinzolamide and 46 levobetaxolol). Patients on no prestudy IOP-lowering therapy randomized to brinzolamide had mean IOP change from baseline ranging from -4.1 mm Hg (week 2) to -5.0 mm Hg (week 6). When all brinzolamide patients are considered, there was little mean change from baseline IOP due to the large number of patients enrolled without a washout of prior IOP-lowering therapy. Levobetaxolol patients had mean change from baseline, ranging from -1.8 mm Hg (week 6) to -2.9 mm Hg (week 2). Levobetaxolol patients on no prestudy therapy had mean IOP change from baseline ranging from -2.9 mm Hg (week 12) to -4.0 mm Hg (week 2). Brinzolamide was more efficacious for glaucoma associated with systemic or ocular abnormalities and less efficacious for primary congenital glaucoma. Levobetaxolol was most efficacious for primary congenital glaucoma. Adverse events were predominantly nonserious and did not interrupt patient continuation in the study. Conclusions: Both brinzolamide and levobetaxolol were well tolerated. Both drugs provided clinically relevant IOP reductions for patients not on a previous medication, although efficacy is, in part, contingent upon diagnosis.{A figure is presented}.

AB - Purpose: To describe the safety and clinical response on elevated intraocular pressure (IOP) of brinzolamide and levobetaxolol in pediatric patients under 6 years of age. Methods: A double-masked, randomized design. Pediatric patients were randomized to brinzolamide suspension, 1%, or levobetaxolol suspension, 0.5%, both dosed twice daily. IOPs at 9 AM were taken at screening, baseline, and weeks 2, 6, and 12. A descriptive study with mean change from baseline IOP, the primary efficacy parameter. Results: Seventy-eight evaluable patients (32 brinzolamide and 46 levobetaxolol). Patients on no prestudy IOP-lowering therapy randomized to brinzolamide had mean IOP change from baseline ranging from -4.1 mm Hg (week 2) to -5.0 mm Hg (week 6). When all brinzolamide patients are considered, there was little mean change from baseline IOP due to the large number of patients enrolled without a washout of prior IOP-lowering therapy. Levobetaxolol patients had mean change from baseline, ranging from -1.8 mm Hg (week 6) to -2.9 mm Hg (week 2). Levobetaxolol patients on no prestudy therapy had mean IOP change from baseline ranging from -2.9 mm Hg (week 12) to -4.0 mm Hg (week 2). Brinzolamide was more efficacious for glaucoma associated with systemic or ocular abnormalities and less efficacious for primary congenital glaucoma. Levobetaxolol was most efficacious for primary congenital glaucoma. Adverse events were predominantly nonserious and did not interrupt patient continuation in the study. Conclusions: Both brinzolamide and levobetaxolol were well tolerated. Both drugs provided clinically relevant IOP reductions for patients not on a previous medication, although efficacy is, in part, contingent upon diagnosis.{A figure is presented}.

UR - http://www.scopus.com/inward/record.url?scp=45549094626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45549094626&partnerID=8YFLogxK

U2 - 10.1016/j.jaapos.2007.11.004

DO - 10.1016/j.jaapos.2007.11.004

M3 - Article

C2 - 18289898

AN - SCOPUS:45549094626

VL - 12

JO - Journal of AAPOS

JF - Journal of AAPOS

SN - 1091-8531

IS - 3

ER -